On December 11, 2020 XNK Therapeutics AB ("XNK") reported its collaboration agreement with Israel-based Cellect Biotechnology ("Cellect") to develop the next generation version of XNK’s innovative technology platform (Press release, CellProtect Nordic Pharmaceuticals, DEC 11, 2020, View Source [SID1234574490]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Cellect will work to further improve XNK Therapeutics’ technology platform for targeting cancer across a wide range of indications. Cellect’s functional cell selection technology has the potential to significantly improve the consistency and manufacturing efficiency in autologous cell therapies.

"I am excited that we will be able to continue developing the next generation of XNK Therapeutics’ technology platform in collaboration with Cellect," said Johan Liwing, CEO of XNK Therapeutics.

"We recognize the growing interest in NK cells and decided to work with XNK Therapeutics for further dissemination of our Apograft technology," said Dr. Shai Yarkoni, CEO of Cellect Biotechnology.